Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Schizophrenia

  Free Subscription


19.08.2019

1 Acta Psychiatr Scand
1 Compr Psychiatry
2 J Clin Psychopharmacol
1 Mol Psychiatry
1 Neuropsychopharmacology
1 Psychiatry Res
1 Psychol Med
12 Schizophr Res


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Acta Psychiatr Scand

  1. CURKOVIC M, Borovecki A
    The Use of Placebo in Schizophrenia Relapse Prevention Studies: Scientific or Ethical Debate?
    Acta Psychiatr Scand. 2019 Aug 13. doi: 10.1111/acps.13085.
    PubMed     Text format     Abstract available


    Compr Psychiatry

  2. NI P, Tian Y, Gu X, Yang L, et al
    Plasma neuropeptides as circulating biomarkers of multifactorial schizophrenia.
    Compr Psychiatry. 2019;94:152114.
    PubMed     Text format     Abstract available


    J Clin Psychopharmacol

  3. YANG N, Li S, Liu S, Lv Y, et al
    Insulin Resistance-Related Proteins Are Overexpressed in Patients and Rats Treated With Olanzapine and Are Reverted by Pueraria in the Rat Model.
    J Clin Psychopharmacol. 2019;39:214-219.
    PubMed     Text format     Abstract available

  4. SANTOS-CASADO M, Garcia-Avello A
    Systematic Review of Gender Bias in the Clinical Trials of New Long-Acting Antipsychotic Drugs.
    J Clin Psychopharmacol. 2019;39:264-272.
    PubMed     Text format     Abstract available


    Mol Psychiatry

  5. ZHANG X, Yang M, Du X, Liao W, et al
    Glucose disturbances, cognitive deficits and white matter abnormalities in first-episode drug-naive schizophrenia.
    Mol Psychiatry. 2019 Aug 13. pii: 10.1038/s41380-019-0478.
    PubMed     Text format     Abstract available


    Neuropsychopharmacology

  6. HO NF, Holt DJ, Cheung M, Iglesias JE, et al
    Correction: Progressive decline in hippocampal CA1 volume in individuals at ultra-high-risk for psychosis who do not remit: findings from the longitudinal youth at risk study.
    Neuropsychopharmacology. 2019 Aug 14. pii: 10.1038/s41386-019-0477.
    PubMed     Text format     Abstract available


    Psychiatry Res

  7. THOMAS N, Gurvich C, Hudaib AR, Gavrilidis E, et al
    Dissecting the syndrome of schizophrenia: Associations between symptomatology and hormone levels in women with schizophrenia.
    Psychiatry Res. 2019;280:112510.
    PubMed     Text format     Abstract available


    Psychol Med

  8. VAN OS J, Pries LK, Delespaul P, Kenis G, et al
    Replicated evidence that endophenotypic expression of schizophrenia polygenic risk is greater in healthy siblings of patients compared to controls, suggesting gene-environment interaction. The EUGEI study.
    Psychol Med. 2019 Aug 15:1-14. doi: 10.1017/S003329171900196.
    PubMed     Text format     Abstract available


    Schizophr Res

  9. OH K, Kim W, Shen G, Piao Y, et al
    Classification of schizophrenia and normal controls using 3D convolutional neural network and outcome visualization.
    Schizophr Res. 2019 Aug 5. pii: S0920-9964(19)30314.
    PubMed     Text format     Abstract available

  10. KRIEGER I, Tzur Bitan D, Comaneshter D, Cohen A, et al
    Increased risk of smoking-related illnesses in schizophrenia patients: A nationwide cohort study.
    Schizophr Res. 2019 Aug 6. pii: S0920-9964(19)30338.
    PubMed     Text format     Abstract available

  11. FANG SC, Huang CY, Liao DL, Hsu CC, et al
    Associations among antipsychotics, metabolism-related diseases, and cataracts in patients with schizophrenia: A retrospective cohort study.
    Schizophr Res. 2019 Aug 6. pii: S0920-9964(19)30329.
    PubMed     Text format     Abstract available

  12. BURTON CZ, Tso IF, Carrion RE, Niendam T, et al
    Baseline psychopathology and relationship to longitudinal functional outcome in attenuated and early first episode psychosis.
    Schizophr Res. 2019 Aug 5. pii: S0920-9964(19)30328.
    PubMed     Text format     Abstract available

  13. SEVILLA-LLEWELLYN-JONES J, Perez J, Cano-Dominguez P, de-Luis-Matilla A, et al
    Clinical personality traits and parental bonding in patients with recent onset of psychosis.
    Schizophr Res. 2019 Aug 6. pii: S0920-9964(19)30332.
    PubMed     Text format    

  14. KIM E, Keskey Z, Kang M, Kitchen C, et al
    Validation of oxidative stress assay for schizophrenia.
    Schizophr Res. 2019 Aug 6. pii: S0920-9964(19)30337.
    PubMed     Text format     Abstract available

  15. AVERY SN, Armstrong K, Blackford JU, Woodward ND, et al
    Impaired relational memory in the early stage of psychosis.
    Schizophr Res. 2019 Aug 8. pii: S0920-9964(19)30340.
    PubMed     Text format     Abstract available

  16. MEHTA UM, Keshavan MS
    Leveraging neurological "soft" signs in the prediction of schizophrenia: A 35-year follow-up case illustration.
    Schizophr Res. 2019 Aug 8. pii: S0920-9964(19)30339.
    PubMed     Text format    

  17. SHUHAMA R, Carmo LSRD, Busatto Filho G, Santos JLF, et al
    From where we came: Absence of internal migration effect on psychosis in two case-control Brazilian samples.
    Schizophr Res. 2019 Aug 8. pii: S0920-9964(19)30322.
    PubMed     Text format    

  18. AMIRI AM, Hiremath SV, Salzer MS, Snethen G, et al
    Predicting physical activity levels in individuals with schizophrenia through integrated global positioning system and accelerometer data.
    Schizophr Res. 2019 Aug 9. pii: S0920-9964(19)30307.
    PubMed     Text format    

  19. KINDLER J, Michel C, Schultze-Lutter F, Felber G, et al
    Functional and structural correlates of abnormal involuntary movements in psychosis risk and first episode psychosis.
    Schizophr Res. 2019 Aug 9. pii: S0920-9964(19)30312.
    PubMed     Text format     Abstract available

  20. SPALTHOFF R, Degenhardt F, Awasthi S, Heilmann-Heimbach S, et al
    Effects of a neurodevelopmental genes based polygenic risk score for schizophrenia and single gene variants on brain structure in non-clinical subjects: A preliminary report.
    Schizophr Res. 2019 Aug 6. pii: S0920-9964(19)30341.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: